系统性红斑狼疮患者CD4+ T细胞对外源性白细胞介素-2反应不佳
该研究比较了健康人与系统性红斑狼疮(SLE)患者CD4+ T细胞亚群产生白细胞介素-2(IL-2)、干扰素-γ(IFNγ)、IL-4和IL-17A的情况,并检测了CD4+ T细胞对外源性IL-2的信号反应。结果显示SLE患者naive CD4+ T细胞产生IL-2存在缺陷,且外源性IL-2诱导的JAK-3/STAT-5磷酸化和细胞增殖均受损,提示设计SLE的IL-2治疗试验需谨慎。
要点
- SLE患者naive CD4+ T细胞产生IL-2存在缺陷。
- SLE患者CD4+ T细胞对外源性IL-2的JAK-3/STAT-5磷酸化受损。
- SLE患者CD4+ T细胞对外源性IL-2的增殖反应受损。
核心结论
- SLE患者CD4+ T细胞存在IL-2产生改变以及IL-2介导的信号和增殖反应受损。
- 设计SLE患者的IL-2治疗试验需要谨慎,并应考虑恢复CD4+ T细胞对IL-2敏感性的方法。
研究设计与样本
- 研究比较了健康受试者和SLE患者CD4+ T细胞亚群的细胞因子产生。
- 通过佛波醇肉豆蔻酸乙酸酯和离子霉素刺激后胞内染色,以及抗CD3/抗CD28刺激后酶联免疫吸附试验评估细胞因子产生。
- 通过检测JAK-3/STAT-5磷酸化检查IL-2信号通路,通过羧基荧光素琥珀酰亚胺酯稀释检查IL-2诱导的细胞增殖。
主要发现
- IL-2产生缺陷主要见于naive CD4+ T细胞。
- SLE患者与健康受试者之间IFNγ、IL-4和IL-17A的产生无显著差异。
- 与健康受试者相比,SLE患者CD4+ T细胞对外源性IL-2的JAK-3/STAT-5磷酸化和增殖均受损。
临床怎么用
- SLE患者CD4+ T细胞对IL-2反应不佳,提示IL-2治疗试验设计需谨慎。
- 可考虑探索恢复CD4+ T细胞对IL-2敏感性的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-γ (IFNγ), IL-4, and IL-17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL-2. METHODS: Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution. RESULTS: Production of IL-2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects. CONCLUSION: These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL-2 should be considered.
引用
- Comte D, Karampetsou MP, Kis-Toth K, et al. Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin-2. Arthritis Rheumatol. 2017. PMID: 27992687. doi:10.1002/art.40014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。